X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) to Post Q3 2024 Earnings of ($0.19) Per Share, Brookline Capital Management Forecasts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at Brookline Capital Management reduced their Q3 2024 earnings estimates for shares of X4 Pharmaceuticals in a note issued to investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.15). The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.48) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals' Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.66) EPS and FY2025 earnings at ($0.06) EPS.

Separately, HC Wainwright boosted their price target on shares of X4 Pharmaceuticals from $3.00 to $5.00 and gave the stock a "buy" rating in a research report on Tuesday.

X4 Pharmaceuticals Price Performance

XFOR stock traded down $0.02 during trading on Thursday, hitting $1.08. The company had a trading volume of 3,089,891 shares, compared to its average volume of 2,601,016. The business has a 50 day moving average of $1.16 and a 200 day moving average of $0.93. The firm has a market capitalization of $181.38 million, a price-to-earnings ratio of -1.80 and a beta of 0.51. The company has a current ratio of 5.34, a quick ratio of 5.34 and a debt-to-equity ratio of 1.07. X4 Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $2.58.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last posted its earnings results on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.05.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 52,500 shares of the business's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $46,200.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other X4 Pharmaceuticals news, CEO Paula Ragan sold 49,678 shares of the company's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $43,716.64. Following the transaction, the chief executive officer now owns 765,068 shares of the company's stock, valued at $673,259.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam S. Mostafa sold 52,500 shares of the firm's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $46,200.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 185,708 shares of company stock valued at $170,428. Corporate insiders own 1.08% of the company's stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in X4 Pharmaceuticals in the 3rd quarter worth about $37,000. Barclays PLC increased its position in shares of X4 Pharmaceuticals by 334.8% in the third quarter. Barclays PLC now owns 382,134 shares of the company's stock worth $417,000 after acquiring an additional 294,255 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of X4 Pharmaceuticals during the third quarter valued at approximately $678,000. Kingdon Capital Management L.L.C. lifted its position in shares of X4 Pharmaceuticals by 76.0% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company's stock valued at $2,913,000 after acquiring an additional 1,500,000 shares in the last quarter. Finally, Stonepine Capital Management LLC lifted its position in shares of X4 Pharmaceuticals by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company's stock valued at $5,748,000 after acquiring an additional 668,422 shares in the last quarter. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.